Lutetium Lu 177 vipivotide tetraxetan (Pluvicto)

From HemOnc.org - A Hematology Oncology Wiki
Revision as of 18:50, 16 October 2021 by Jwarner (talk | contribs) (Created page with "==Preliminary data== #'''VISION:''' Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, Tagawa ST, Nordquist LT, Vaishampayan N, El-Haddad G, Park CH, Beer TM, Armour...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Preliminary data

  1. VISION: Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, Tagawa ST, Nordquist LT, Vaishampayan N, El-Haddad G, Park CH, Beer TM, Armour A, Pérez-Contreras WJ, DeSilvio M, Kpamegan E, Gericke G, Messmann RA, Morris MJ, Krause BJ; VISION Investigators. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2021 Sep 16;385(12):1091-1103. Epub 2021 Jun 23. link to original article link to PMC article PubMed NCT03511664
Retrieved from "https://hemonc.org/w/index.php?title=Lutetium_Lu_177_vipivotide_tetraxetan_(Pluvicto)&oldid=52830"